Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

Respiration

Volumn 89, Issue 6, 2015, Pages 515-524

  Speich, Rudolf ^a   Ulrich, Silvia ^a   Domenighetti, Guido ^b   Huber, Lars C ^a   Fischler, Manuel ^a   Treder, Ursula ^a   Breitenstein, Alexander ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Ospedale La Carita   (Switzerland)

Author keywords

Adverse effects; Imatinib; Pulmonary arterial hypertension; Subdural hematoma; Treatment

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; HEMOGLOBIN; IMATINIB; PROSTANOID; SILDENAFIL; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR MORTALITY; CASE REPORT; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EDEMA; FEMALE; FOLLOW UP; HEADACHE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE PRESSURE; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IDIOPATHIC DISEASE; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LUNG VASCULAR RESISTANCE; MAJOR DEPRESSION; MALE; MIDDLE AGED; MONOTHERAPY; MORBIDITY; MUSCULOSKELETAL DISEASE; NAUSEA; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OXYGEN SATURATION; PATIENT DECISION MAKING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; QUALITY OF LIFE; RISK FACTOR; SCORING SYSTEM; SUBDURAL HEMATOMA; SUICIDE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING; CHEMICALLY INDUCED; ECHOGRAPHY; HYPERTENSION, PULMONARY; LONGITUDINAL STUDY; REMISSION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; ECHOCARDIOGRAPHY; FEMALE; HEMATOMA, SUBDURAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; IMATINIB MESYLATE; INTERNATIONAL NORMALIZED RATIO; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937524507     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000381923     Document Type: Article

References (35)

1. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Blaukovitsch M, Zabel P, Hauber HP: Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension. Recent Pat Cardiovasc Drug Discov 2009; 4: 142-149.
3. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G, Emilie D: Plateletderived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-559.
4. Li JC, Pan JQ, Huang GQ, Tan X, Sun WD, Liu YJ, Wang XL: Expression of PDGF-beta receptor in broilers with pulmonary hypertension induced by cold temperature and its association with pulmonary vascular remodeling. Res Vet Sci 2010; 88: 116-121.
5. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B: Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009; 34: 662-668.
6. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, Herve P, Emilie D, Eddahibi S, Simonneau G, Souza R, Humbert M: Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
7. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
8. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316.
9. Ghofrani HA, Seeger W, Grimminger F: Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
10. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M: Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
11. Patterson KC, Weissmann A, Ahmadi T, Farber HW: Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153.
12. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
13. Speich R, Treder U, Domenighetti G, Huber L, Ulrich S: Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension. Int J Clin Pharm 2014; 36: 256-260.
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
15. Cima K, Twiss J, Speich R, McKenna SP, Grunig E, Kahler CM, Ehlken N, Treder U, Crawford SR, Huber LC, Ulrich S: The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). Health Qual Life Outcomes 2012; 10: 110.
16. Chemla D, Castelain V, Humbert M, Hebert JL, Simonneau G, Lecarpentier Y, Herve P: New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004; 126: 1313-1317.
17. Hoeper M, Barst R, Galié N, Hassoun P, Morrell N, Peacock A, Simonneau G: Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) (abstract). Eur Respir J 2011; 38(suppl 55):50s.
18. Baechli H, Nordmann A, Bucher HC, Gratzl O: Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev 2004; 27: 263-266.
19. Mori K, Maeda M: Surgical treatment of chronic subdural hematoma in 500 consecutive cases: clinical characteristics, surgical outcome, complications, and recurrence rate. Neurol Med Chir (Tokyo) 2001; 41: 371-381.
20. Nayil K, Ramzan A, Sajad A, Zahoor S, Wani A, Nizami F, Laharwal M, Kirmani A, Bhat R: Subdural hematomas: an analysis of 1, 181 Kashmiri patients. World Neurosurg 2012; 77: 103-110.
21. SambasiVan M: An overview of chronic subdural hematoma: experience with 2, 300 cases. Surg Neurol 1997; 47: 418-422.
22. Hoeper M, Barst R, Galié N, Hassoun P, Morrell N, Peacock A, Simonneau G: Long-term safety and efficacy of imatinib in pulmonary arterial (abstract). Eur Respir J 2012; 40(suppl 56):583s.
23. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S: Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
24. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA, Grimminger F, Grunig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA: Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128-1138.
25. Hoeper MM, Opitz C, Olschewski H, Ulrich S, Speich R, Behr J, Halank M, Wilkens H, Klose H, Lange TJ, Grunig E, Seeger W, Ewert R, Borst MM, Welte T, Rosenkranz S, Ghofrani HA: Imatinib for pulmonary arterial hypertension (in German). Dtsch Med Wochenschr 2014; 139(suppl 4):S151-S154.
26. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL: Primary pulmonary hpyertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
27. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM: Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129: 57-65.
28. Foelholm R, Waltimo O: Epidemiology of chronic subdural haematoma. Acta Neurochir (Wien) 1975; 32: 247-250.
29. Kudo H, Kuwamura K, Izawa I, Sawa H, Tamaki N: Chronic subdural hematoma in elderly people: present status on Awaji Island and epidemiological prospect. Neurol Med Chir (Tokyo) 1992; 32: 207-209.
30. Asghar M, Adhiyaman V, Greenway MW, Bhowmick BK, Bates A: Chronic subdural haematoma in the elderly-a North Wales experience. J R Soc Med 2002; 95: 290-292.
31. Hylek EM, Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
32. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH: Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118: 511-520.
33. Louis L, Bair N, Banjac S, Dweik RA, Tonelli AR: Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs. Pulm Circ 2012; 2: 518-521.
34. Quintas-Cardama A, Han X, Kantarjian H, Cortes J: Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009; 114: 261-263.
35. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ: Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 2006; 169: 2054-2065.